ABSTRACT
Background Tuberculosis (TB) remains a significant global health challenge, particularly with the rise of drug-resistant strains, such as Pyrazinamide (PZA)-resistant TB. This resistance hampers treatment effectiveness. Currently, there’s a lack of affordable and precise quantitative tests for detecting PZA resistance, highlighting the need for accessible diagnostic tools. Our study introduces a direct, accurate, and accessible susceptibility test for PZA resistance by quantifying pirazinoic acid (POA).
Methods We analyzed 264 TB-positive samples (MP and TBN) to assess PZA susceptibility by measuring POA production. This was done using the MODS-Wayne qualitative assay and our developed quantitative approach (MODS-WQ). For MODS-WQ, TBN samples were processed in 7H9 media (MODS-WQ 7H9) and MP samples in citrate buffer (MODS-WQ CB). We measured POA levels using spectrophotometry against a calibration curve, with PZA susceptibility determined by a composite standard. We also investigated the correlation between POA levels and pyrazinamidase mutations. Multidrug-resistant samples were assessed using the MODS test, and statistical analyses were conducted.
Results Approximately 23.48% of the samples showed PZA resistance, which included 62.8% of the multidrug-resistant (MDR) samples. The MODS-Wayne assay demonstrated an 87.8% sensitivity and 95.9% specificity for MP samples, and 62.5% sensitivity with 93.7% specificity for TBN samples. The MODS-WQ identified specific cut-off points—123.25 μM for MODS-WQ 7H9 and 664.7 μM for MODS-WQ CB—with corresponding sensitivities of 81.25% and 92.31%, and specificities of 77.22% and 95.93%. Significantly lower POA levels were observed in samples with mutations in the metal binding site compared to mutations on the enzyme’s periphery.
Conclusions The citrate-buffered MODS-WQ demonstrates high sensitivity and specificity in quantifying POA. It offers a significant improvement over qualitative methods, effectively overcoming their subjectivity limitations in PZA resistance detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially funded by Grand Challenge Canada (contract 037-2014-FONDECYT)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Committee on Research Ethics (CIEI) of the Universidad Peruana Cayetano Heredia (Code 331-34-21) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
